Monday, October 3, 2022


Biotechnology News Magazine

Scipher Medicine Increases Patients Access for Prisma by Expanding Intended Use in Autoimmune Patients

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Scipher Medicine, is a precision immunology company matching patients with the most effective therapy. Today the company announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.

PrismRA is a first-of-its-kind molecular signature test that informs personalized treatment decisions for RA patients at any point in the clinical journey.
Specialty drug spend is one of the largest contributors to increasing healthcare costs.

An estimated $552 billion is wasted each year when patients are prescribed drugs they don’t respond to. Close to 90% of RA patients failing methotrexate are prescribed the world’s largest selling drug class, tumor necrosis factor inhibitor (TNFi) therapies. Yet the majority of patients don’t respond and cycle through unnecessary dose escalations and multiple ineffective TNFi drugs until they are prescribed alternative effective therapy.

PrismRA accurately predicts inadequate response to TNFi therapy enabling such patients to start alternative effective FDA-approved therapies at initial therapy selection and, now with the expanded indication, during any point in the patient journey in order to reach treatment goals faster. The expanded use was validated in the Network-004 study with 73 sites across the United States and published in Rheumatology and Therapy. PrismRA can now serve over 600,000 patients in the Unites States and 11.5 million globally suffering from RA.

“With its expanded utility, PrismRA can reduce cost of care by more than $19,000 per patient per year by avoiding ineffective therapy and dose escalations,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “We are adding and will keep adding more indications and drugs for PrismRA, including JAK and IL therapies so that one simple blood test empowers physicians with extensive evidence-based therapy selection solutions.”

Expanded access to PrismRA testing is urgently needed as RA patients not responding to prescribed therapy experience increased cardiovascular disease, 83% more surgeries, increased opioid usage, and twice as many emergency visits and hospitalizations.
“There is an urgent need for personalized medicine in rheumatology,” said James E. Mossell III, D.O., F.A.C.R. from Arthritis and Osteoporosis Center of South Georgia affiliated with Tift Regional Medical Center. “A precision medicine approach that is used when starting or modifying RA therapy will be a powerful tool for providers and allow significantly more patients to reach their treatment targets sooner.”
Since its launch in the fall of 2020, more than 10% of the rheumatologists in the US have ordered PrismRA. Over 1.3 million Americans and 20 million patients globally suffer from rheumatoid arthritis.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine